3 stories from 3 sources
Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
A curated list of other prominent stories from this day.
Researchers found that aggressive small cell cancers that lose the RB gene become dependent on the protein E2F3 to survive. In lab models, blocking E2F3 halted tumor growth, and the work suggests some existing FDA-approved drugs could be repurposed to target this dependency.
3:26 PMScienceDailyNew York City health officials reported a Legionnaires disease cluster on the Upper East Side with at least 10 confirmed infections. Investigators have not yet identified the source and are continuing environmental testing and case-finding.
10:12 AMGothamistWith Ebola cases increasing in Congo and Uganda, developers are fast-tracking vaccines aimed at the Bundibugyo strain. IAVI says a candidate could enter human trials by the end of this year.
1:00 AMBloomberg MarketsSummary
Researchers found that aggressive small cell cancers that lose the RB gene become dependent on the protein E2F3 to survive. In lab models, blocking E2F3 halted tumor growth, and the work suggests some existing FDA-approved drugs could be repurposed to target this dependency.
Why it matters
It identifies a practical target in cancers that have long resisted progress and could shorten the path to new treatments by enabling biomarker-driven, repurposing-focused trials.
Summary
New York City health officials reported a Legionnaires disease cluster on the Upper East Side with at least 10 confirmed infections. Investigators have not yet identified the source and are continuing environmental testing and case-finding.
Why it matters
Legionella outbreaks can expand quickly when the source is still active, making early identification and water-system control the difference between a contained cluster and a citywide public health event.
Summary
With Ebola cases increasing in Congo and Uganda, developers are fast-tracking vaccines aimed at the Bundibugyo strain. IAVI says a candidate could enter human trials by the end of this year.
Why it matters
Earlier trials could shorten the time to a deployable vaccine for a less-common Ebola strain that is driving current outbreaks.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!